[144] Revolution Medicines, Inc. SEC Filing

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) Form 144 discloses a proposed sale of 2,131 shares of common stock through ETRADE with an aggregate market value of $99,198.05, with an approximate sale date of 09/15/2025 on NASDAQ. The securities originated from restricted stock unit grants received from the issuer on 05/01/2023 (1,253 shares), 03/01/2024 (412 shares) and 03/01/2025 (466 shares), each noted as payment for services rendered. The filing also reports a prior sale by the same person of 2,173 shares on 06/16/2025 generating $86,550.59. The filer certifies no undisclosed material adverse information is known.

Positive

• Compliance disclosure: The filer has provided required Rule 144 details including grant dates, share counts, broker and planned sale date.
• Transparency on origin: The filing specifies that the securities were issued as restricted stock unit grants and lists the dates and amounts.

Negative

• Insider selling: The filing records a proposed sale of 2,131 shares and a recent sale of 2,173 shares, indicating insider liquidity events.

Insights

Securities Analyst

TL;DR: Officer/insider discloses planned sale of 2,131 RSU-derived shares via ETRADE, and a recent sale of 2,173 shares.

The filing documents a routine Rule 144 notice: the shares to be sold were issued as restricted stock unit grants and are being disclosed ahead of a proposed sale on 09/15/2025. The filing includes specifics on grant dates and amounts and records a recent sale on 06/16/2025 with gross proceeds of $86,550.59. From a compliance and transparency standpoint this meets Rule 144 notice requirements; the disclosed amounts appear modest in absolute terms based on the data provided.

Corporate Governance Expert

TL;DR: Proper insider-sale disclosure was made for RSU-derived shares; documentation includes acquisition and prior sale details.

The notice provides required detail about the origin of the securities (RSU grants listed by grant date and amounts), the planned broker and venue (ETRADE on NASDAQ), and a prior sale within the three-month lookback. The signer affirms no undisclosed material adverse information. This is a procedural governance disclosure enabling market transparency.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE Financial Corporation 3 Edison Drive Alpharetta GA 30005	2131	99198.05	186933190	09/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	05/01/2023	Restricted stock unit grant	Issuer			1253	05/01/2023	Services rendered
Common Stock	03/01/2024	Restricted stock unit grant	Issuer			412	03/01/2024	Services rendered
Common Stock	03/01/2025	Restricted stock unit grant	Issuer			466	03/01/2025	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Wei Lin c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	06/16/2025	2173	86550.59

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the RVMD Form 144 propose to sell?

The notice proposes sale of 2,131 shares of common stock with aggregate market value $99,198.05.

When is the approximate sale date listed on the Form 144?

The approximate sale date is listed as 09/15/2025.

Through which broker will the RVMD shares be sold?

The broker named is ETRADE Financial Corporation, address shown in the filing.

How were the securities acquired according to the filing?

The securities were acquired as restricted stock unit grants on 05/01/2023 (1,253), 03/01/2024 (412), and 03/01/2025 (466).

Did the filer sell any RVMD shares recently?

Yes, the filing reports a sale on 06/16/2025 of 2,173 shares for gross proceeds of $86,550.59.